DP3 Type 1 Diabetes Targeted Research Award
Harvesting the Neuroimaging Cornucopia for Pancreatic Islet Imaging Reagents for Diabetes Research (DP3)
This Funding Opportunity Announcement (FOA) encourage DP3 applications from institutions/organizations to allow researchers with access to major clinical nuclear molecular imaging facilities to screen their libraries of existing positron emission tomography (PET) or single photon emission computed tomography (SPECT) neuroimaging agents that are already approved for use in human subjects research in order to find tools to enhance in vivo study of the beta cells of the human pancreatic islet. Diabetes ensues with the loss or dysfunction of beta cells and the inability to monitor their mass is an enormous barrier to understanding the natural history of human diabetes or the course of disease in an individual patient. Because human pancreatic islet beta cells are distinct from those of rodent models of diabetes and yet have many of the neurotransmitter systems found in the human brain, screening of existing human neuroimaging agents directly in human subjects and human tissues may be a cost-efficient way to identify promising beta cell imaging agents. Archived PET/SPECT scans of human abdomen or dosimetry data may be useful to identify imaging agents that are retained in human pancreas. Excess neuroimaging agent made for a human brain study could be tested in human pancreas tissue slices and isolated human islets. An image of the abdominal region could be obtained from human subjects at the conclusion of their neuroimaging research protocol, in order to ascertain signal and therefore potential specific binding in the pancreas. Promising agents identified in any of these or similar screens would likely need to be further developed for imaging pancreatic islet cell mass, function, or disease state.
|Letter of Intent Due Date|
January 20, 2014
|Application Due Date||February 20, 2014, by 5:00 PM local time of applicant organization.|